Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Omeros Corporation stock
Learn how to easily invest in Omeros Corporation stock.
Omeros Corporation is a biotechnology business based in the US. Omeros Corporation shares (OMER) are listed on the NASDAQ and all prices are listed in US Dollars. Omeros Corporation employs 213 staff and has a trailing 12-month revenue of around $90.5 million.
How to buy shares in Omeros Corporation
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – OMER – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
Omeros Corporation stock price (NASDAQ: OMER)Use our graph to track the performance of OMER stocks over time.
Omeros Corporation shares at a glance
|Latest market close||$3.32|
|52-week range||$1.86 - $14.61|
|50-day moving average||$4.88|
|200-day moving average||$5.01|
|Wall St. target price||$20.00|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$3.14|
Buy Omeros Corporation shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Omeros Corporation stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Omeros Corporation price performance over time
|1 week (2022-09-21)||-15.52%|
|1 month (2022-08-26)||-13.09%|
|3 months (2022-06-28)||12.16%|
|6 months (2022-03-24)||-46.10%|
|1 year (2021-09-28)||-75.92%|
|2 years (2020-09-28)||-66.63%|
|3 years (2019-09-27)||16.4|
|5 years (2017-09-28)||21.05|
Is Omeros Corporation stock undervalued or overvalued?
Valuing Omeros Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Omeros Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Omeros Corporation's P/E ratio
Omeros Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, Omeros Corporation shares trade at around 1x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Omeros Corporation financials
|Revenue TTM||$90.5 million|
|Gross profit TTM||$-71,397,000|
|Return on assets TTM||-39.51%|
|Return on equity TTM||0%|
|Market capitalisation||$219.6 million|
TTM: trailing 12 months
Omeros Corporation share dividends
We're not expecting Omeros Corporation to pay a dividend over the next 12 months.
Have Omeros Corporation's shares ever split?
Omeros Corporation's shares were split on 1 October 2009.
Omeros Corporation share price volatility
Over the last 12 months, Omeros Corporation's shares have ranged in value from as little as $1.86 up to $14.61. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Omeros Corporation's is 1.1782. This would suggest that Omeros Corporation's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Omeros Corporation overview
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR" (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington. .
Omeros Corporation in the news
Omeros COVID-19 Treatment Reduced Mortality Risk, But Biased Data Rendered Analysis Meaningless
Omeros Corporation Reports Narsoplimab Treatment Results in Critically Ill COVID-19 Patients in I-SPY COVID Trial
I-SPY COVID Trial Sponsored by Quantum Leap Healthcare Collaborative Reports Assessment of Narsoplimab for Treatment of Critically Ill Patients With COVID-19
Frequently asked questionsWhat percentage of Omeros Corporation is owned by insiders or institutions?
Currently 4.028% of Omeros Corporation shares are held by insiders and 38.035% by institutions. How many people work for Omeros Corporation?
Latest data suggests 213 work at Omeros Corporation. When does the fiscal year end for Omeros Corporation?
Omeros Corporation's fiscal year ends in December. Where is Omeros Corporation based?
Omeros Corporation's address is: The Omeros Building, Seattle, WA, United States, 98119 What is Omeros Corporation's ISIN number?
Omeros Corporation's international securities identification number is: US6821431029 What is Omeros Corporation's CUSIP number?
Omeros Corporation's Committee on Uniform Securities Identification Procedures number is: 682143102
More guides on Finder
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
How to buy Lead Real Estate Co. (LRE) stock when it goes public
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
How to buy Third Harmonic Bio (THRD) stock
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
How to buy LINKBANCORP (LNKB) stock
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
We’ve rounded up stats on some of the most popular wheat stocks, along with information on how these stocks compare and how to invest.
Ask an Expert